We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
+$27.8M
Cap. Flow %
7.12%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
151
DELISTED
Nuvalent
NUVL
– –
-5,000
Closed -$382K
NVO
152
CALL
Novo Nordisk
NVO
$208B
– –
-100,000
Closed -$6.9M
OLMA icon
153
Olema Pharmaceuticals
OLMA
$1B
– –
-253,657
Closed -$1.52M
PFE icon
154
CALL
Pfizer
PFE
$143B
– –
-200,000
Closed -$4.85M
PHAT icon
155
Phathom Pharmaceuticals
PHAT
$708M
– –
-40,294
Closed -$386K
PRTA icon
156
CALL
Prothena Corp
PRTA
$425M
– –
-100,000
Closed -$607K
QURE icon
157
CALL
uniQure
QURE
$3.03B
– –
-104,100
Closed -$1.45M
REPL icon
158
Replimune Group
REPL
$941M
– –
-32,483
Closed -$208K
RVMD icon
159
CALL
Revolution Medicines
RVMD
$39.9B
– –
-200,000
Closed -$7.36M
RVPH
160
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-200,000
Closed -$1.52M
SCPH
161
DELISTED
scPharmaceuticals
SCPH
– –
-217,623
Closed -$1.11M
SMMT icon
162
Summit Therapeutics
SMMT
$10.4B
– –
-932
Closed -$22.6K
SMMT icon
163
PUT
Summit Therapeutics
SMMT
$10.4B
– –
-50,000
Closed -$1.06M
SPRY icon
164
CALL
ARS Pharmaceuticals
SPRY
$509M
– –
-280,700
Closed -$4.9M
SRRK icon
165
Scholar Rock
SRRK
$5.67B
– –
-62,926
Closed -$2.2M
TNGX icon
166
CALL
Tango Therapeutics
TNGX
$4.43B
– –
-200,000
Closed -$1.02M
VRDN icon
167
Viridian Therapeutics
VRDN
$2.09B
– –
-122,061
Closed -$1.71M
VRTX icon
168
Vertex Pharmaceuticals
VRTX
$121B
– –
-10,000
Closed -$4.45M
XBI icon
169
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-100,000
Closed -$8.29M
ZLAB icon
170
Zai Lab
ZLAB
$2.06B
– –
-3,785
Closed -$13.2K
3 4 5 6
7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners deployed $27.8M of net new capital in Q3 2025, opening 75 new positions and adding to 15 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $5.86M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 49% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $10.2M trimmed.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.